X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1285) 1285
humans (1232) 1232
mice (943) 943
rank ligand - metabolism (688) 688
female (630) 630
male (625) 625
osteoclasts - drug effects (523) 523
rank ligand - antagonists & inhibitors (515) 515
osteoprotegerin (498) 498
osteoclasts - metabolism (488) 488
rankl (472) 472
rank ligand (455) 455
osteoclasts - cytology (411) 411
cells, cultured (406) 406
osteoporosis (381) 381
receptor activator (372) 372
differentiation (344) 344
denosumab (337) 337
expression (332) 332
cell differentiation - drug effects (323) 323
receptor activator of nuclear factor-kappa b (315) 315
endocrinology & metabolism (311) 311
osteoclastogenesis (300) 300
rank ligand - genetics (289) 289
osteoclast (288) 288
bone resorption (273) 273
cell biology (264) 264
osteoclasts (249) 249
cells (244) 244
mice, inbred c57bl (234) 234
kappa-b ligand (229) 229
osteoclast differentiation (227) 227
biochemistry & molecular biology (225) 225
cell line (225) 225
signal transduction (225) 225
middle aged (224) 224
oncology (220) 220
rank ligand - pharmacology (213) 213
bone (212) 212
osteoblasts - metabolism (212) 212
musculoskeletal diseases (207) 207
osteoprotegerin - metabolism (202) 202
gene expression (200) 200
trance protein (191) 191
bone-resorption (189) 189
rheumatology (189) 189
signal transduction - drug effects (188) 188
dentistry, oral surgery & medicine (186) 186
rats (185) 185
adult (184) 184
dentistry (184) 184
cytokines (182) 182
osteoclasts - physiology (182) 182
activation (180) 180
inflammation (179) 179
osteogenesis - drug effects (179) 179
analysis (178) 178
nf-kappa-b (176) 176
osteoclasts - pathology (173) 173
postmenopausal women (172) 172
aged (171) 171
nf-kappa b - metabolism (171) 171
osteoblasts - drug effects (169) 169
rheumatoid-arthritis (166) 166
bone neoplasms - secondary (165) 165
cell differentiation (162) 162
orthopedics (160) 160
bone resorption - metabolism (157) 157
in-vitro (153) 153
bones (152) 152
immunology (151) 151
pharmacology & pharmacy (149) 149
osteoblasts (148) 148
research (146) 146
receptor activator of nuclear factor-kappa b - metabolism (143) 143
bone density conservation agents - therapeutic use (142) 142
bone and bones - metabolism (141) 141
rank (141) 141
disease models, animal (137) 137
ligands (137) 137
osteoprotegerin ligand (137) 137
tumor-necrosis-factor (137) 137
antibodies, monoclonal, humanized (134) 134
antibodies, monoclonal - therapeutic use (129) 129
bone loss (129) 129
cancer (128) 128
ligand (128) 128
zoledronic acid (128) 128
membrane glycoproteins - metabolism (126) 126
proteins (125) 125
carrier proteins - metabolism (124) 124
receptor (123) 123
resorption (121) 121
health aspects (120) 120
mice, knockout (120) 120
medicine & public health (119) 119
gene-expression (114) 114
rna, messenger - metabolism (114) 114
diphosphonates - therapeutic use (113) 113
reverse transcriptase polymerase chain reaction (113) 113
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2010) 2010
Japanese (37) 37
German (11) 11
French (8) 8
Spanish (6) 6
Hungarian (4) 4
Russian (4) 4
Italian (3) 3
Polish (3) 3
Portuguese (3) 3
Chinese (2) 2
Danish (2) 2
Croatian (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
...B ligand, on bone mineral density and fractures in such men. Use of denosumab was associated with increased bone mineral density at all sites and reduction in the incidence of new vertebral fractures... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
PloS one, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e80873
...) and RAW264.7 macrophages stimulated by the receptor activator of nuclear factor-kappaB (NF-kappa B) ligand (RANKL). Acteoside pretreatment also prevented bone resorption by mature osteoclasts in a dose-dependent manner... 
REHMANNIA-GLUTINOSA | ACTIVATION | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | RECEPTOR | DIFFERENTIATION | MOLECULAR-BASIS | CELL | MICE LACKING | OSTEOPOROSIS | BONE-RESORPTION | Interleukin-6 - antagonists & inhibitors | RANK Ligand - metabolism | Reactive Oxygen Species - metabolism | NF-kappa B - metabolism | Osteoclasts - cytology | Bone Marrow Cells - drug effects | Female | Cell Differentiation | Interleukin-1beta - biosynthesis | p38 Mitogen-Activated Protein Kinases - metabolism | Interleukin-1beta - antagonists & inhibitors | Phenols - pharmacology | Proto-Oncogene Proteins c-fos - antagonists & inhibitors | Cell Survival - drug effects | Glucosides - pharmacology | NF-kappa B - antagonists & inhibitors | Ovariectomy | Signal Transduction | Bone Marrow Cells - cytology | NFATC Transcription Factors - metabolism | Gene Expression Regulation | Proto-Oncogene Proteins c-fos - metabolism | p38 Mitogen-Activated Protein Kinases - genetics | Antioxidants - pharmacology | Macrophages - cytology | Osteoclasts - metabolism | Mice, Inbred ICR | Bone Resorption - prevention & control | RANK Ligand - genetics | Macrophages - metabolism | Reactive Oxygen Species - antagonists & inhibitors | Animals | NF-kappa B - genetics | RANK Ligand - antagonists & inhibitors | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Interleukin-6 - biosynthesis | Macrophages - drug effects | Proto-Oncogene Proteins c-fos - genetics | Mice | NFATC Transcription Factors - antagonists & inhibitors | Tumor Necrosis Factor-alpha - biosynthesis | Bone Marrow Cells - metabolism | Osteoclasts - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | NFATC Transcription Factors - genetics | Osteoprogenitor cells | Transcription factors | Phosphorylation | Interleukin | Arthritis | Activation | Kinases | Macrophages | Interleukin 6 | Antioxidants | Bone resorption | Osteoporosis | Bone growth | Bone marrow | Tumor necrosis factor-TNF | Biocompatibility | Inhibition | Pretreatment | Bone loss | TRANCE protein | c-Fos protein | NF-κB protein | Cytokines | c-Jun protein | Pharmacology | Inflammation | Dentistry | Tumor necrosis factor-α | Orthodontics | Medicine | Osteoclastogenesis | Stem cells | Ligands | Osteoclasts | Laboratory animals | Differentiation
Journal Article
Nature communications, ISSN 2041-1723, 10/2016, Volume 7, Issue 1, p. 13176
.... Here we show that PTH inhibition of SOST (sclerostin), a WNT antagonist, requires HDAC4 and HDAC5, whereas PTH stimulation of RANKL, a stimulator of bone resorption, requires CRTC2... 
CHONDROCYTE HYPERTROPHY | HISTONE DEACETYLASE 4 | TARGETED DISRUPTION | PTH | MULTIDISCIPLINARY SCIENCES | RECEPTOR ACTIVATOR | GENE-EXPRESSION | BONE HOMEOSTASIS | DOWN-REGULATION | SALT-INDUCIBLE KINASES | KAPPA-B LIGAND | Osteocytes - drug effects | RNA, Small Interfering - genetics | RANK Ligand - metabolism | Humans | Glycoproteins - metabolism | Parathyroid Hormone - pharmacology | Bone and Bones - drug effects | Protein Isoforms - metabolism | Parathyroid Hormone - metabolism | Bone and Bones - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Phosphorylation - drug effects | Osteogenesis - genetics | Protein-Serine-Threonine Kinases - metabolism | Bone and Bones - cytology | Glycoproteins - genetics | Histone Deacetylases - genetics | Osteocytes - metabolism | Signal Transduction | Intercellular Signaling Peptides and Proteins | Osteocytes - cytology | Osteogenesis - drug effects | Gene Expression Regulation | Glycoproteins - antagonists & inhibitors | Protein-Serine-Threonine Kinases - genetics | Histone Deacetylases - metabolism | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Mice, Knockout | RANK Ligand - genetics | Transcription Factors - metabolism | Animals | RANK Ligand - antagonists & inhibitors | Active Transport, Cell Nucleus - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Primary Cell Culture | Protein Isoforms - antagonists & inhibitors | Protein Isoforms - genetics | RNA, Small Interfering - metabolism | Cell and Molecular Biology | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cell- och molekylärbiologi | Medicinska och farmaceutiska grundvetenskaper
Journal Article
The Journal of immunology (1950), ISSN 1550-6606, 2004, Volume 172, Issue 10, pp. 5940 - 5947
Journal Article
Journal Article
Journal of endodontics, ISSN 0099-2399, 2013, Volume 39, Issue 12, pp. 1557 - 1561
... osteoclasts and osteoblasts (3) . In several studies, identified receptor activators of nuclear factor kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) have been shown... 
Endocrinology & Metabolism | Dentistry | mineral trioxide aggregate | TRAP | receptor activator for nuclear factor kappaB | RAW 264.7 macrophages | Calcium silicate cement | OSTEOBLAST | CELLS | RANKL | CEMENT | receptor activator for nuclear factor kappa B | RATIO | DENTISTRY, ORAL SURGERY & MEDICINE | CALCIUM | EXPRESSION | COMMUNICATION | Spectrophotometry, Atomic - methods | Cathepsin K - drug effects | Tartrate-Resistant Acid Phosphatase | TNF Receptor-Associated Factor 6 - antagonists & inhibitors | Dose-Response Relationship, Drug | Silicon - pharmacology | Culture Media | Cell Culture Techniques | Cell Death - drug effects | Acid Phosphatase - drug effects | Oxides - administration & dosage | Calcium Compounds - pharmacology | Silicates - pharmacology | Cell Line | Cell Survival - drug effects | NF-kappa B - antagonists & inhibitors | Materials Testing | Calcium Compounds - administration & dosage | Silicon - administration & dosage | Oxides - pharmacology | Animals | Aluminum Compounds - administration & dosage | RANK Ligand - antagonists & inhibitors | Cell Differentiation - drug effects | Silicates - administration & dosage | Macrophages - drug effects | Silicate Cement - pharmacology | Aluminum Compounds - pharmacology | Cell Proliferation - drug effects | Isoenzymes - drug effects | Mice | Silicate Cement - administration & dosage | Drug Combinations | Osteoclasts - drug effects | Medical colleges
Journal Article
Journal Article
Journal Article